Arrowhead Pharmaceuticals ARWR
NASDAQ ARWR
$59.76 +0.84 (+1.43%)
As of: Oct 21, 2026 · 2:14 PM EDT

Arrowhead Pharmaceuticals (ARWR) Short term Debt (2024 - 2026)

Updated

Arrowhead Pharmaceuticals (ARWR) reported Short term Debt of $40 million for fiscal Q3 2026 (quarter ended Jun 30, 2026), unchanged from $40 million a year earlier and unchanged from the prior quarter.

Analysis

Arrowhead Pharmaceuticals (ARWR) Short term Debt (2024 - 2026) Analysis & Trends

Dating back to fiscal Q1 2025, Arrowhead Pharmaceuticals' Short term Debt record includes 7 quarters.

  • Five-year quarterly Short term Debt spans a low of $1.63 million in fiscal Q1 2025 and a high of $65 million in fiscal Q2 2025.
  • Per Business Quant data, the three fiscal quarters before Q3 2026 came in at $40 million (Q2 2026), $40 million (Q1 2026) and $40 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,133.19 Bn 1,101.77 Bn 19.71 Bn
2 Johnson & Johnson 616.03 Bn 534.56 Bn 17.26 Bn
3 AbbVie 501.09 Bn 474.20 Bn 12.70 Bn
4 Merck 366.82 Bn 321.20 Bn 12.21 Bn
5 Novartis Ag 297.82 Bn 261.81 Bn 11.24 Bn
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn
7 Amgen 235.89 Bn 191.29 Bn 7.24 Bn
8 Gilead Sciences 190.64 Bn 164.84 Bn 6.22 Bn
9 Pfizer 169.32 Bn 115.96 Bn 10.94 Bn
10 Arrowhead Pharmaceuticals 8.57 Bn 3.35 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 40.00 Mn
Mar 31, 2026 40.00 Mn
Dec 31, 2025 40.00 Mn
Sep 30, 2025 40.00 Mn
Jun 30, 2025 40.00 Mn
Mar 31, 2025 65.00 Mn
Dec 31, 2024 1.63 Mn
API Access

Arrowhead Pharmaceuticals Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=ARWR&period=max&api_key=YOUR_API_KEY